Drug
Isis Apoc Iii RX
Isis Apoc Iii RX: highest development phase Phase 2, developed by Ionis Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Ionis Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ISIS apoC-III Rx NCT01529424 | Phase 2 | Hypertriglyceridemia |
Latest
No recent events.
Follow Isis Apoc Iii RX on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.